Citadel Advisors
TARS icon

Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Buy
+163,997
New +$11.5M ﹤0.01% 3062
2025
Q4 		– Sell
-43,281
Closed -$2.57M – 14045
2025
Q3 		$2.57M Sell
43,281
-185,965
-81% -$9.16M ﹤0.01% 5577
2025
Q2 		$9.29M Sell
229,246
-763,396
-77% -$34.4M ﹤0.01% 3136
2025
Q1 		$51M Buy
992,642
+913,301
+1,151% +$45.1M 0.01% 1129
2024
Q4 		$4.39M Sell
79,341
-305,126
-79% -$13.9M ﹤0.01% 4168
2024
Q3 		$12.6M Buy
384,467
+176,978
+85% +$4.97M ﹤0.01% 2578
2024
Q2 		$5.64M Sell
207,489
-11,789
-5% -$396K ﹤0.01% 3562
2024
Q1 		$7.97M Buy
219,278
+176,241
+410% +$5.18M ﹤0.01% 3252
2023
Q4 		$871K Buy
43,037
+37,173
+634% +$621K ﹤0.01% 6950
2023
Q3 		$104K Sell
5,864
-131,753
-96% -$2.33M ﹤0.01% 10845
2023
Q2 		$2.49M Buy
137,617
+85,361
+163% +$1.36M ﹤0.01% 4777
2023
Q1 		$657K Buy
52,256
+31,289
+149% +$458K ﹤0.01% 7728
2022
Q4 		$307K Buy
+20,967
New +$347K ﹤0.01% 9264
2022
Q3 		– Sell
-20,873
Closed -$331K – 13585
2022
Q2 		$305K Sell
20,873
-4,228
-17% -$63.5K ﹤0.01% 9768
2022
Q1 		$422K Buy
+25,101
New +$466K ﹤0.01% 9783

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's TARS Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2026: 163,997 shares worth $11.5M. The stake represents ﹤0.01% of the portfolio and ranks #3062 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TARS as recently as Q3 2025.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 15 quarters since. The position peaked at $51M in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Citadel Advisors held 163,997 shares of Tarsus Pharmaceuticals worth $11.5M as of Q1 2026.
  • Tarsus Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3062 holding.
  • Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.